Maternal lifestyle and infant outcome am j dis child

Maternal lifestyle and infant outcome. Am J Dis Child.
1993;147(10):1062 – 5.
26. Dideriksen D, Pottegard A, Hallas J, Aagaard L, Damkier P. First
trimester exposure to methylphenidate Basic Clin. Pharm
Toxicol. 2013;112(2):73 – 6.
27. Kallen B, Borg N, Reis M. The use of central nervous system
active drugs during pregnancy. Pharmaceuticals. 2013;6(10):
1221 – 86.
28. Pottegård A, Hallas J, Andersen JT, Løkkegaard EC, Dideriksen
D, Aagaard L, et al . First-trimester exposure to methylphenidate: a
population-based cohort study. J Clin Psychiatry. 2014;75(1):e88 –
93.
29. Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K.
Use of ADHD medication during pregnancy from 1999 to 2010: a
Danish register-based study. Pharmacoepidemiol Drug Saf.
2014;23(5):526 – 33.
30. Diav-Citrin O, Shechtman S, Arnon J, Wajnberg R, Borisch C,
Beck E, et al . Methylphenidate in pregnancy: A multicenter, pro-
spective, comparative, observational study. J. Clin. Psychiatry.
2016;77(9):1176 – 81.
31. Bro SP, Kjaersgaard MI, Parner ET, Sørensen MJ, Olsen J, Bech
BH, et al . Adverse pregnancy outcomes after exposure to methyl-
phenidate or atomoxetine during pregnancy. Clin Epidemiol.
2015;7:139 – 47.
32. Hackett LP, Kristensen JH, Hale TW, Paterson R, Ilett KF.
Methylphenidate and breast feeding. Ann Pharmacother.
2006;40:1890 – 1.
33. Spigset O, Brede WR, Zahken K. Excretion of methylphenidate
in breast milk. Am J Psych. 2007;164:348 – 54.
34. Schaefer C, Peters P, Miller RK editors: Drugs during pregnancy
and lactation, third edition. Elsevier publ. 2015; methylphenidate
pp 768 – 769.
35. Golub M, Costa L, Crofton K, Frank D, Fried P, Gladen B, et al .
NTP-CERHR expert panel report on the reproductive and de-
velopmental toxicity of amphetamine and methamphetamine.
Birth Defects Res (Part B). 2005;74:471 – 584.
36. Nora JJ, Vargo TA, Nora AH, Love KE, McNamara DG.
Dexamphetamine: a possible environmental trigger in cardiovas-
cular malformations. Lancet. 1970;1(7659):1290 – 1.
37. Milkovich L, Van den Berg BJ. Effects of antenatal exposure to
anorectic drugs. Am J Obstet Gynecol. 1977;129:637 – 42.
38. Heinonen OP. Birth Defects and Drugs in Pregnancy. Littleton:
Publishing Sciences Group Inc; 1977.
39. Little BB, Snell LM, Gilstrap LC 3rd. Methamphetamine abuse
during pregnancy: outcome and fetal effects. Obstet Gynecol.
1988;72:541 – 4.
40. Draper ES, Rankin J, Tonks AM, Abrams KR, Field DJ, Clarke
M, et al . Recreational drug use: a major risk factor for
gastroschisis? Am J Epidemiol. 2008;167(4):485 – 91.
41. Felix RJ, Chambers CD, Dick LM, Johnson KA, Jones KL.
Prospective pregnancy outcome in women exposed to amphet-
amines. Teratology. 2000;61:441. Abstract
42. Wright TE, Schueter R, Tellei J, Sauvage L. Methamphetamine
and pregnancy outcome. J Addict Med. 2015;9(2):111 – 7.
43. Eriksson M, Larsson G, Zetterström R. Amphetamine addiction
and pregnancy II. Pregnancy, delivery and the neonatal period.
Socio-medical aspects. Acta Obstet Gynecol Scand. 1981;60:253 –
9.
44. Nguyen D, Smith LM, Lagasse LL, Derauf C, Grant P, Shah R,
et al . Intrauterine growth of infants exposed to prenatal metham-
phetamine: results from the infant development, environment,
and lifestyle study. J Pediatr. 2010;157(2):337 – 9.